French biotech (ABVX) has emerged as the most likely acquisition target among biotechs in 2026, significantly outpacing others, while liver drug developer Madrigal Pharmaceuticals (MDGL) has become ...

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.

Swiss oncology powerhouse BeOne Medicines (ONC) has emerged as one of 2025's top performers in a sector often plagued by volatility. Year-to-date, ONC shares have rocketed 75%, outpacing many peers ...

A medical device company from Ireland, a biotech startup developing cancer therapeutics from Pennsylvania and a venture studio focused on women’s health from Massachusetts are among eight recipients ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied about 35% over the past six months (as of Nov. 20, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 12%). Year to ...

A bipartisan group of senators and representatives introduced legislation to establish a National Biopharmaceutical Manufacturing Center of Excellence (COE), inspired by recommendations from the ...

Since their initial rollout in 1994, genetically modified organisms (GMOs, aka biotechnology) have erupted in a firestorm of controversy. Derided as grotesque “Frankenfoods,” opponents have claimed ...

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of AUM) IVW: $11.0 million (8.6% of AUM) ...

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM Top five holdings after the filing: ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of ...

Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came ...